000			02146 a2200577 4500
005			20250515041423.0
264		0	_c20070205
008			200702s 0 0 eng d
022			_a0167-6997
024	7		_a10.1007/s10637-006-9008-5 _2doi
040			_aNLM _beng _cNLM
100	1		_aJames, Jehana
245	0	0	_aPhase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. _h[electronic resource]
260			_bInvestigational new drugs _cFeb 2007
300			_a41-8 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_a2-Methoxyestradiol
650	0	4	_aAdministration, Oral
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Agents, Phytogenic _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aArea Under Curve
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aDocetaxel
650	0	4	_aDrug Administration Schedule
650	0	4	_aEstradiol _xadverse effects
650	0	4	_aFatigue _xchemically induced
650	0	4	_aFemale
650	0	4	_aHalf-Life
650	0	4	_aHumans
650	0	4	_aMatrix Metalloproteinase 2 _xblood
650	0	4	_aMatrix Metalloproteinase 9 _xblood
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Metastasis
650	0	4	_aNeoplasm Recurrence, Local
650	0	4	_aTaxoids _xadverse effects
650	0	4	_aTreatment Outcome
650	0	4	_aTubulin Modulators _xadministration & dosage
650	0	4	_aUrinalysis
650	0	4	_aVascular Cell Adhesion Molecule-1 _xblood
650	0	4	_aVascular Endothelial Growth Factor A _xurine
700	1		_aMurry, Daryl J
700	1		_aTreston, Anthony M
700	1		_aStorniolo, Anna Maria
700	1		_aSledge, George W
700	1		_aSidor, Carolyn
700	1		_aMiller, Kathy D
773	0		_tInvestigational new drugs _gvol. 25 _gno. 1 _gp. 41-8
856	4	0	_uhttps://doi.org/10.1007/s10637-006-9008-5 _zAvailable from publisher's website
999			_c16552176 _d16552176